Micron Biomedical
Micron Biomedical is a clinical-stage life science company and the leader in dissolvable microarray-based technology for needle-free delivery of vaccines and therapeutics. The company's mission is to radically expand access to treatments and vaccines, improve global health outcomes, and transform how vaccines and drugs are administered. Micron's proprietary technology enables painless, thermostable, and self-administered drug and vaccine delivery, eliminating the need for cold chain logistics and reducing infrastructure barriers. The company is recognized for its innovative approach to overcoming vaccine hesitancy and access challenges, and is rapidly advancing toward commercializing its technology for global impact. Micron partners with leading global health organizations and has secured significant funding to accelerate the development and commercialization of its needle-free solutions.
Micron Biomedical
What We Do
A proprietary, dissolvable microarray 'button' technology for needle-free, painless, and thermostable delivery of vaccines and therapeutics. Enables self-administration and reduces cold chain requirements.
A microarray patch-based, needle-free version of the measles-rubella vaccine, shown to be safe and immunogenic in children as young as 9 months. Supported by the Gates Foundation and recognized as a top innovation for global immunization.
A next-generation rotavirus vaccine delivered via dissolvable microarray patch, currently in first-in-human clinical trials in collaboration with Emory University and the CDC.
Development of a needle-free, microarray patch-delivered mRNA-based influenza vaccine in collaboration with Zipcode Bio, supported by a $2 million BARDA award.
A dissolving microneedle patch for long-acting contraception, delivering levonorgestrel for over a month with a single application. Licensed exclusively to Micron Biomedical.
Microneedle patch for inactivated rotavirus vaccine (IRV), developed in collaboration with the CDC for future clinical evaluation.
Infectious Diseases
Regenerative Medicine
Key People
EVP, Chief Technology Officer, Co-founder
EVP, Chief Financial Officer
EVP, Head of Technical Operations, Co-founder
Advisor
Scientific Advisor
News & Updates
Awarded $2 million by BARDA for collaboration with Zipcode Bio to develop mRNA-based broad protecting flu vaccine without needles.
CEPI and Micron Biomedical Accelerate Needle-Free Vaccines against Disease X with $3.7 Million Grant
Received $3.7 million from CEPI to advance needle-free vaccine technology for rapid response to emerging diseases.
Secured $43 million in grant support, including from the Gates Foundation, to improve measles and rubella vaccine coverage and accelerate the world’s first phase 2 trial of needle-free technology in infants.
Finalist in the Prix Galien USA Award for breakthrough scientific innovation in the start-up category.
Received the Biotech Medical Innovation Award at Boston Biotech Week for advancing biopharmaceutical product and technology.
Recognized among leading biotechnology organizations at the ViE & WVCDC Awards.
Micron Biomedical extended its Series A financing to more than $33 million, led by J2 Ventures and the Global Health Investment Corporation, to accelerate commercialization and expand manufacturing of its needle-free therapeutics and vaccines.
BBC highlights the advantages of Micron's technology over needle injections, including ease of use, reduced need for cold storage, and reduced needle fear.
Science Magazine reports on the collaboration between Micron, Emory, and CDC for a novel rotavirus vaccine delivered via microneedle patch.
Endpoints News covers Micron's $16M+ Series A extension and plans for commercial launch of its vaccine button technology.
Newsweek features Micron's technology in the context of Bill Gates' vision for transforming vaccine delivery.
The World Economic Forum highlights Micron’s technology and its potential to increase vaccine uptake.
Reuters Spotlights Micron’s Progress Toward Mass Production of Its Proprietary Microarray Technology
Reuters covers Micron’s advancements in scaling up production of its microarray patch technology.
FiercePharma discusses Micron’s progress in bringing its microarray patch technology to market.
BMJ Journal features the impact and cost-effectiveness of Micron’s microarray technology.
Labiotech provides a comprehensive overview of how Micron Biomedical is disrupting access challenges with needle-free vaccines, highlighting the company's leadership, recent funding, and the potential of its dissolvable microarray technology to improve access to vaccines and therapeutics globally.
First-ever CDC-sponsored clinical trial of a vaccine delivered via patch technology, utilizing Micron’s dissolvable microarray technology.
CEO Steven Damon spoke at the Bio International Convention about overcoming challenges in public perception and advancing access to needle-free technology.
Micron Biomedical presented data on the safety and efficacy of its microarray technology at the World Vaccine Congress.
Micron Biomedical showcased its breakthrough microarray technology at the Modern Vaccines, Adjuvants & Delivery Systems (MVADS25) conference in Glasgow, highlighting its needle-free, thermostable technology that can deliver vaccines without cold storage, syringes, or clinicians.
Micron Biomedical presented its vaccine technology at the SXSW conference, sharing perspectives on how technology is shaping pandemic preparedness and the future of home-based, needle-free vaccine delivery.
Micron Biomedical participated in the J2 Ventures Annual Meeting, joining a portfolio of innovative companies addressing global challenges.